The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region

Ann Rheum Dis. 2015 Jan;74(1):311-4. doi: 10.1136/annrheumdis-2014-206237. Epub 2014 Oct 23.

Abstract

Background: In a subset of patients, anti tumour necrosis factor (TNF) therapeutic antibodies are immunogenic, resulting in the formation of antidrug antibodies (ADAs). Neutralising ADAs compete with TNF for its binding site and reduces the effective serum concentration, causing clinical non-response. It is however unknown to which extent ADAs are neutralising.

Objectives: To study which proportion of antibodies to human(ised) anti-TNF (adalimumab, golimumab, certolizumab) as well as chimeric anti-TNF (infliximab) is neutralising.

Methods: Neutralising capacity of ADAs was assessed using a TNF competition assay in ADA-positive sera of patients treated with adalimumab (n=21), golimumab (n=4), certolizumab (n=9) or infliximab (n=34) sent in to our diagnostic department.

Results: In 34 sera with ADAs to adalimumab, golimumab or certolizumab, >97% of the antibodies were neutralising. In 34 sera with ADAs to infliximab >90% of the antibodies were neutralising. Further characterisation of the broader antibody response to infliximab revealed that non-neutralising antibodies to infliximab do not target murine domains, but may bind infliximab-unique domains not involved in TNF binding (located outside the paratope).

Conclusions: Our study shows that ADAs to human(ised) as well as chimeric anti-TNF therapeutic antibodies are largely neutralising. This highly restricted ADA response suggests an immunodominant role for the paratope of anti-TNF therapeutics.

Keywords: Anti-TNF; Rheumatoid Arthritis; TNF-alpha.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adalimumab
  • Antibodies / immunology
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal, Humanized / immunology*
  • Antibodies, Monoclonal, Murine-Derived
  • Antibodies, Neutralizing / immunology*
  • Antirheumatic Agents / immunology*
  • Binding Sites, Antibody / immunology*
  • Certolizumab Pegol
  • Humans
  • Immunoglobulin Fab Fragments / immunology
  • Infliximab
  • Polyethylene Glycols
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Antibodies
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived
  • Antibodies, Neutralizing
  • Antirheumatic Agents
  • Immunoglobulin Fab Fragments
  • Tumor Necrosis Factor-alpha
  • Polyethylene Glycols
  • golimumab
  • Infliximab
  • Adalimumab
  • Certolizumab Pegol